戊酸雌二醇联合甲羟孕酮治疗子宫内膜异位症的疗效及对血清CA125、CA199、VEGF水平的影响

目的:探讨戊酸雌二醇联合甲羟孕酮治疗子宫内膜异位症的疗效及对血清糖类抗原125(CA125)、糖类抗原199(CA199)、血管内皮生长因子(VEGF)水平的影响。方法:选择本院2016年6月～2018年1月收治的134例子宫内膜异位症患者,按随机数字表法分为对照组(n=76)和观察组(n=58),对照组采用甲羟孕酮治疗,观察组在对照组基础上联合戊酸雌二醇治疗,比较两组临床疗效,治疗前后血清CA125、CA199、VEGF水平,囊肿直径、月经不调评分、痛经评分和不良反应发生情况。结果:观察组总有效率高于对照组,差异有统计学意义(P0.05)。治疗前,两组血清CA125、CA199、VEGF水平,囊肿直径、月经不调评分、痛经评分比较差异无统计学意义(P0.05);治疗后,两组血清CA125、CA199、VEGF水平、囊肿直径、月经不调评分及痛经评分均下降,观察组低于对照组,差异有统计学意义(P0.05)。两组均有乏力、失眠及潮热发生,组间总副反应发生率差异无统计学意义(P0.05)。结论:戊酸雌二醇联合甲羟孕酮能够提高子宫内膜异位症的疗效,有效降低血清CA125、CA199及VEGF水平,安全性较高。

Curative Effect of Estradiol Valerate Combined with Medroxyprogesterone in Treatment Endometriosis and Its Impact on Serum Levels of CA125, CA199 and VEGF

ABSTRACT Objective: To investigate the curative effect of estradiol valerate combined with medroxyprogesterone in the treatment of endometriosis and its impact on serum levels of carbohydrate antigen 125 (CA125), carbohydrate antigen 199(CA199) and vascular endothelial growth factor (VEGF). Methods: 134 cases of endometriosis who treated from June 2016 to January 2018 in our hospital, according to random number table method these patients were divided into the control group (n=76) and observation group (n=58), the control group was treated with medroxyprogesterone and the observation group was treated with estradiol valerate on the basis of the control group, then clinical curative effect, serum levels of CA125, CA199 and VEGF cyst diameter, menstruation to be not moved a grade, dysmenorrhea before and after treatment, and adverse reactions occur in both group were compared. Results: the total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant(P<0.05). Before treatment, serum levels of CA125, CA199 and VEGF, cyst diameter, menstrual irregularness score and dysmenorrhea score of the two groups were no significant difference(P>0.05). After treatment, serum levels of CA125, CA199 and VEGF, cyst diameter, dysmenorrhea score and dysmenorrhea score of the two groups were all decreased, and the difference between the observation group and the control group was statistically significant(P<0.05). Fatigue, insomnia and hot flashes occurred in both groups, and there was no statistically significant difference in the incidence of total adverse reactions between the two groups(P>0.05). Conclusion: Estradiol valerate combined with medroxyprogesterone can improve the efficacy of endometriosis, effectively reduce the level of serum CA125, CA199 and VEGF, and has a high safety.